Selected research
Industry Research
Vinorelbine Industry Research Report 2026
Market perspective
The global Vinorelbine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vinorelbine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vinorelbine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vinorelbine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vinorelbine include TEVA Pharms, Shenzhen Main Luck Pharmaceuticals Inc., Shanxi Powerdone Pharmaceutics Co., Ltd., Qilu Pharmaceutical (Hainan) Co., Ltd., Mylan, Luoxin Pharmaceutical Group Co., Ltd., Hangzhou Minsheng Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vinorelbine market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vinorelbine Market by Company
TEVA Pharms
Shenzhen Main Luck Pharmaceuticals Inc.
Shanxi Powerdone Pharmaceutics Co., Ltd.
Qilu Pharmaceutical (Hainan) Co., Ltd.
Mylan
Luoxin Pharmaceutical Group Co., Ltd.
Hangzhou Minsheng Pharmaceutical Group Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Fresenius Kabi
Nanjing Cuccess Pharmaceutical Co., Ltd
Beijing SL Pharm
West-Ward Pharmaceuticals Corp.
Sinopharm A-Think Pharmaceutical Co., Ltd.
Pierre Fabre Pharmaceuticals, Inc.
Hospira, Inc.
EBEWE Pharma (Sandoz A Novartis Division)
Dr. Reddy's Laboratories
Vinorelbine Segment by Type
Oral
Injection
Vinorelbine Segment by Application
Breast Cancer
Non-small Cell Lung Cancer
Other
Vinorelbine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vinorelbine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vinorelbine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vinorelbine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vinorelbine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vinorelbine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vinorelbine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Breast Cancer
- Non-small Cell Lung Cancer
- Other
Companies covered
- TEVA Pharms
- Shenzhen Main Luck Pharmaceuticals Inc.
- Shanxi Powerdone Pharmaceutics Co., Ltd.
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Mylan
- Luoxin Pharmaceutical Group Co., Ltd.
- Hangzhou Minsheng Pharmaceutical Group Co., Ltd.
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Fresenius Kabi
- Nanjing Cuccess Pharmaceutical Co., Ltd
- Beijing SL Pharm
- West-Ward Pharmaceuticals Corp.
- Sinopharm A-Think Pharmaceutical Co., Ltd.
- Pierre Fabre Pharmaceuticals, Inc.
- Hospira, Inc.
- EBEWE Pharma (Sandoz A Novartis Division)
- Dr. Reddy's Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vinorelbine Market Size (2021-2032)
- 2.2.2 Global Vinorelbine Sales (2021-2032)
- 2.2.3 Global Vinorelbine Market Average Price (2021-2032)
- 2.3 Vinorelbine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Vinorelbine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Non-small Cell Lung Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vinorelbine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vinorelbine Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Vinorelbine Revenue of Manufacturers (2021-2026)
- 3.4 Global Vinorelbine Average Price by Manufacturers (2021-2026)
- 3.5 Global Vinorelbine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vinorelbine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vinorelbine, Product Type & Application
- 3.8 Global Manufacturers of Vinorelbine, Established Date
- 3.9 Global Vinorelbine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 TEVA Pharms
- 4.1.1 TEVA Pharms Company Information
- 4.1.2 TEVA Pharms Business Overview
- 4.1.3 TEVA Pharms Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 TEVA Pharms Vinorelbine Product Portfolio
- 4.1.5 TEVA Pharms Recent Developments
- 4.2 Shenzhen Main Luck Pharmaceuticals Inc.
- 4.2.1 Shenzhen Main Luck Pharmaceuticals Inc. Company Information
- 4.2.2 Shenzhen Main Luck Pharmaceuticals Inc. Business Overview
- 4.2.3 Shenzhen Main Luck Pharmaceuticals Inc. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shenzhen Main Luck Pharmaceuticals Inc. Vinorelbine Product Portfolio
- 4.2.5 Shenzhen Main Luck Pharmaceuticals Inc. Recent Developments
- 4.3 Shanxi Powerdone Pharmaceutics Co., Ltd.
- 4.3.1 Shanxi Powerdone Pharmaceutics Co., Ltd. Company Information
- 4.3.2 Shanxi Powerdone Pharmaceutics Co., Ltd. Business Overview
- 4.3.3 Shanxi Powerdone Pharmaceutics Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanxi Powerdone Pharmaceutics Co., Ltd. Vinorelbine Product Portfolio
- 4.3.5 Shanxi Powerdone Pharmaceutics Co., Ltd. Recent Developments
- 4.4 Qilu Pharmaceutical (Hainan) Co., Ltd.
- 4.4.1 Qilu Pharmaceutical (Hainan) Co., Ltd. Company Information
- 4.4.2 Qilu Pharmaceutical (Hainan) Co., Ltd. Business Overview
- 4.4.3 Qilu Pharmaceutical (Hainan) Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qilu Pharmaceutical (Hainan) Co., Ltd. Vinorelbine Product Portfolio
- 4.4.5 Qilu Pharmaceutical (Hainan) Co., Ltd. Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Vinorelbine Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Luoxin Pharmaceutical Group Co., Ltd.
- 4.6.1 Luoxin Pharmaceutical Group Co., Ltd. Company Information
- 4.6.2 Luoxin Pharmaceutical Group Co., Ltd. Business Overview
- 4.6.3 Luoxin Pharmaceutical Group Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Luoxin Pharmaceutical Group Co., Ltd. Vinorelbine Product Portfolio
- 4.6.5 Luoxin Pharmaceutical Group Co., Ltd. Recent Developments
- 4.7 Hangzhou Minsheng Pharmaceutical Group Co., Ltd.
- 4.7.1 Hangzhou Minsheng Pharmaceutical Group Co., Ltd. Company Information
- 4.7.2 Hangzhou Minsheng Pharmaceutical Group Co., Ltd. Business Overview
- 4.7.3 Hangzhou Minsheng Pharmaceutical Group Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hangzhou Minsheng Pharmaceutical Group Co., Ltd. Vinorelbine Product Portfolio
- 4.7.5 Hangzhou Minsheng Pharmaceutical Group Co., Ltd. Recent Developments
- 4.8 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- 4.8.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information
- 4.8.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
- 4.8.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Vinorelbine Product Portfolio
- 4.8.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
- 4.9 Fresenius Kabi
- 4.9.1 Fresenius Kabi Company Information
- 4.9.2 Fresenius Kabi Business Overview
- 4.9.3 Fresenius Kabi Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Fresenius Kabi Vinorelbine Product Portfolio
- 4.9.5 Fresenius Kabi Recent Developments
- 4.10 Nanjing Cuccess Pharmaceutical Co., Ltd
- 4.10.1 Nanjing Cuccess Pharmaceutical Co., Ltd Company Information
- 4.10.2 Nanjing Cuccess Pharmaceutical Co., Ltd Business Overview
- 4.10.3 Nanjing Cuccess Pharmaceutical Co., Ltd Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Nanjing Cuccess Pharmaceutical Co., Ltd Vinorelbine Product Portfolio
- 4.10.5 Nanjing Cuccess Pharmaceutical Co., Ltd Recent Developments
- 4.11 Beijing SL Pharm
- 4.11.1 Beijing SL Pharm Company Information
- 4.11.2 Beijing SL Pharm Business Overview
- 4.11.3 Beijing SL Pharm Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Beijing SL Pharm Vinorelbine Product Portfolio
- 4.11.5 Beijing SL Pharm Recent Developments
- 4.12 West-Ward Pharmaceuticals Corp.
- 4.12.1 West-Ward Pharmaceuticals Corp. Company Information
- 4.12.2 West-Ward Pharmaceuticals Corp. Business Overview
- 4.12.3 West-Ward Pharmaceuticals Corp. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 West-Ward Pharmaceuticals Corp. Vinorelbine Product Portfolio
- 4.12.5 West-Ward Pharmaceuticals Corp. Recent Developments
- 4.13 Sinopharm A-Think Pharmaceutical Co., Ltd.
- 4.13.1 Sinopharm A-Think Pharmaceutical Co., Ltd. Company Information
- 4.13.2 Sinopharm A-Think Pharmaceutical Co., Ltd. Business Overview
- 4.13.3 Sinopharm A-Think Pharmaceutical Co., Ltd. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sinopharm A-Think Pharmaceutical Co., Ltd. Vinorelbine Product Portfolio
- 4.13.5 Sinopharm A-Think Pharmaceutical Co., Ltd. Recent Developments
- 4.14 Pierre Fabre Pharmaceuticals, Inc.
- 4.14.1 Pierre Fabre Pharmaceuticals, Inc. Company Information
- 4.14.2 Pierre Fabre Pharmaceuticals, Inc. Business Overview
- 4.14.3 Pierre Fabre Pharmaceuticals, Inc. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Pierre Fabre Pharmaceuticals, Inc. Vinorelbine Product Portfolio
- 4.14.5 Pierre Fabre Pharmaceuticals, Inc. Recent Developments
- 4.15 Hospira, Inc.
- 4.15.1 Hospira, Inc. Company Information
- 4.15.2 Hospira, Inc. Business Overview
- 4.15.3 Hospira, Inc. Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Hospira, Inc. Vinorelbine Product Portfolio
- 4.15.5 Hospira, Inc. Recent Developments
- 4.16 EBEWE Pharma (Sandoz A Novartis Division)
- 4.16.1 EBEWE Pharma (Sandoz A Novartis Division) Company Information
- 4.16.2 EBEWE Pharma (Sandoz A Novartis Division) Business Overview
- 4.16.3 EBEWE Pharma (Sandoz A Novartis Division) Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 EBEWE Pharma (Sandoz A Novartis Division) Vinorelbine Product Portfolio
- 4.16.5 EBEWE Pharma (Sandoz A Novartis Division) Recent Developments
- 4.17 Dr. Reddy's Laboratories
- 4.17.1 Dr. Reddy's Laboratories Company Information
- 4.17.2 Dr. Reddy's Laboratories Business Overview
- 4.17.3 Dr. Reddy's Laboratories Vinorelbine Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Dr. Reddy's Laboratories Vinorelbine Product Portfolio
- 4.17.5 Dr. Reddy's Laboratories Recent Developments
5 Global Vinorelbine Market Scenario by Region
- 5.1 Global Vinorelbine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vinorelbine Sales by Region: 2021-2032
- 5.2.1 Global Vinorelbine Sales by Region: 2021-2026
- 5.2.2 Global Vinorelbine Sales by Region: 2027-2032
- 5.3 Global Vinorelbine Revenue by Region: 2021-2032
- 5.3.1 Global Vinorelbine Revenue by Region: 2021-2026
- 5.3.2 Global Vinorelbine Revenue by Region: 2027-2032
- 5.4 North America Vinorelbine Market Facts & Figures by Country
- 5.4.1 North America Vinorelbine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vinorelbine Sales by Country (2021-2032)
- 5.4.3 North America Vinorelbine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Vinorelbine Market Facts & Figures by Country
- 5.5.1 Europe Vinorelbine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vinorelbine Sales by Country (2021-2032)
- 5.5.3 Europe Vinorelbine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Vinorelbine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vinorelbine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vinorelbine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vinorelbine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vinorelbine Market Facts & Figures by Country
- 5.7.1 South America Vinorelbine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vinorelbine Sales by Country (2021-2032)
- 5.7.3 South America Vinorelbine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Vinorelbine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vinorelbine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vinorelbine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vinorelbine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Vinorelbine Sales by Type (2021-2032)
- 6.1.1 Global Vinorelbine Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Vinorelbine Sales Market Share by Type (2021-2032)
- 6.2 Global Vinorelbine Revenue by Type (2021-2032)
- 6.2.1 Global Vinorelbine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vinorelbine Revenue Market Share by Type (2021-2032)
- 6.3 Global Vinorelbine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vinorelbine Sales by Application (2021-2032)
- 7.1.1 Global Vinorelbine Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Vinorelbine Sales Market Share by Application (2021-2032)
- 7.2 Global Vinorelbine Revenue by Application (2021-2032)
- 7.2.1 Global Vinorelbine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vinorelbine Revenue Market Share by Application (2021-2032)
- 7.3 Global Vinorelbine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vinorelbine Value Chain Analysis
- 8.1.1 Vinorelbine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vinorelbine Production Mode & Process
- 8.2 Vinorelbine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vinorelbine Distributors
- 8.2.3 Vinorelbine Customers
9 Global Vinorelbine Analyzing Market Dynamics
- 9.1 Vinorelbine Industry Trends
- 9.2 Vinorelbine Industry Drivers
- 9.3 Vinorelbine Industry Opportunities and Challenges
- 9.4 Vinorelbine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst